← NeOnc Technologies Holdings, Inc. Common Stock overview

NeOnc Technologies Holdings, Inc. Common Stock vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

NeOnc Technologies Holdings, Inc. Common Stock (NTHI)

Q3 202617 Jun – 6 Aug 2026

▲4

NeOnc's brain tumor drugs win first foreign clearances and near key data

First international regulatory clearance for NEO212 Abu Dhabi's health department authorized NeOnc to start a Phase 2 trial of NEO212, its oral brain tumor therapy. This is the program's first approval outside the U.S., opening a new region for testing and adding a fresh path toward eventual sales.
A brand-new regulatory milestone that expands the company's clinical reach and potential market.
Second Abu Dhabi clearance covers NEO100 and pediatric gliomas NeOnc received another Abu Dhabi IND for NEO100, allowing adult Phase 1 and 2 studies plus a path to test it in children with high-grade gliomas. This widens the number of patients and uses for its lead drug, raising its long-term sales potential.
A separate new authorization that broadens the NEO100 program into pediatrics and more trials.
FDA feedback clears CMC hurdle for NEO212 The FDA gave written feedback on how NeOnc makes NEO212, and the company decided it was enough to cancel a planned meeting. That removes a possible delay in the drug's manufacturing review, keeping the program on track toward later-stage testing.
A new regulatory step that reduces uncertainty around NEO212's path forward.
Phase 2a data for NEO100 due by end of July NeOnc's NEO100-01 study is fully enrolled, and topline Phase 2a results are expected by the end of July 2026. Positive data could boost confidence in the drug and attract partners or investors; disappointing results would hurt the stock.
A near-term catalyst that could swing the stock sharply depending on results.

July 202617 Jun – 6 Aug 2026

▲4

NeOnc's brain tumor drugs win first foreign clearances and near key data

First international regulatory clearance for NEO212 Abu Dhabi's health department authorized NeOnc to start a Phase 2 trial of NEO212, its oral brain tumor therapy. This is the program's first approval outside the U.S., opening a new region for testing and adding a fresh path toward eventual sales.
A brand-new regulatory milestone that expands the company's clinical reach and potential market.
Second Abu Dhabi clearance covers NEO100 and pediatric gliomas NeOnc received another Abu Dhabi IND for NEO100, allowing adult Phase 1 and 2 studies plus a path to test it in children with high-grade gliomas. This widens the number of patients and uses for its lead drug, raising its long-term sales potential.
A separate new authorization that broadens the NEO100 program into pediatrics and more trials.
FDA feedback clears CMC hurdle for NEO212 The FDA gave written feedback on how NeOnc makes NEO212, and the company decided it was enough to cancel a planned meeting. That removes a possible delay in the drug's manufacturing review, keeping the program on track toward later-stage testing.
A new regulatory step that reduces uncertainty around NEO212's path forward.
Phase 2a data for NEO100 due by end of July NeOnc's NEO100-01 study is fully enrolled, and topline Phase 2a results are expected by the end of July 2026. Positive data could boost confidence in the drug and attract partners or investors; disappointing results would hurt the stock.
A near-term catalyst that could swing the stock sharply depending on results.

Latest17 Jun – 6 Aug 2026

▲4

NeOnc's brain tumor drugs win first foreign clearances and near key data

First international regulatory clearance for NEO212 Abu Dhabi's health department authorized NeOnc to start a Phase 2 trial of NEO212, its oral brain tumor therapy. This is the program's first approval outside the U.S., opening a new region for testing and adding a fresh path toward eventual sales.
A brand-new regulatory milestone that expands the company's clinical reach and potential market.
Second Abu Dhabi clearance covers NEO100 and pediatric gliomas NeOnc received another Abu Dhabi IND for NEO100, allowing adult Phase 1 and 2 studies plus a path to test it in children with high-grade gliomas. This widens the number of patients and uses for its lead drug, raising its long-term sales potential.
A separate new authorization that broadens the NEO100 program into pediatrics and more trials.
FDA feedback clears CMC hurdle for NEO212 The FDA gave written feedback on how NeOnc makes NEO212, and the company decided it was enough to cancel a planned meeting. That removes a possible delay in the drug's manufacturing review, keeping the program on track toward later-stage testing.
A new regulatory step that reduces uncertainty around NEO212's path forward.
Phase 2a data for NEO100 due by end of July NeOnc's NEO100-01 study is fully enrolled, and topline Phase 2a results are expected by the end of July 2026. Positive data could boost confidence in the drug and attract partners or investors; disappointing results would hurt the stock.
A near-term catalyst that could swing the stock sharply depending on results.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.